Shares of Agios Pharmaceuticals closed the previous trading session at 50.36 down -5.15 -9.28% with 1,285,084 shares trading hands. Cantley sold 2,036 shares of the stock in a transaction that occurred on Monday, April 17th. Creative Planning's holdings in Agios Pharmaceuticals were worth $963,000 at the end of the most recent quarter. ARK Investment Management LLC purchased a new stake in Agios Pharmaceuticals during the fourth quarter valued at $190,000. It worsened, as 23 investors sold Agios Pharmaceuticals Inc shares while 45 reduced holdings. Illinois-based Balyasny Asset Management Ltd has invested 0.15% in Agios Pharmaceuticals Inc (NASDAQ:AGIO).
IAMGOLD Corp (USA) (NYSE:IAG) have shown a low EPS growth of -34.60% in the last 5 years and has earnings growth of 99.30% yoy. BlackRock Fund Advisors boosted its stake in Agios Pharmaceuticals by 6.0% in the third quarter. Although past volatility action may help predict the future volatility of a stock, it may also be greatly different when taking into account other factors that may be driving price action during the period of time.
08/08/2016 - Agios Pharmaceuticals, Inc. had its "neutral" rating reiterated by analysts at Goldman Sachs. 223092 shares were traded on Agios Pharmaceuticals, Inc.'s last session.
On 12/31/2016 Agios Pharmaceuticals, Inc. The firm has a 50 day moving average of $43.46 and a 200 day moving average of $47.72. The last close places the company's stock about $2.02 off its 52 week high of $6.8 and $1.77 above the 52 week low of $3.01. Agios Pharmaceuticals's revenue for the quarter was up 264.5% compared to the same quarter past year. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($1.51) by $0.17. For the Current Quarter, 10 analysts are projecting the mean EPS to be $-2.01/share. Agios Pharmaceuticals had a negative net margin of 341.56% and a negative return on equity of 53.39%. The firm's revenue for the quarter was up 264.5% on a year-over-year basis. Analysts forecast that Agios Pharmaceuticals Inc will post ($7.31) EPS for the current year.
TRADEMARK VIOLATION WARNING: This report was originally published by [[site]] and is owned by of [[site]]. If you are reading this story on another domain, it was illegally copied and reposted in violation of United States & worldwide copyright law.
Support for marijuana legalization at all-time high
Recreational marijuana - the kind you smoke without a doctor's note - wasn't legal anywhere in the United States five years ago. Trump's spokesman and some of his Cabinet members have said marijuana legalization may not be tolerated any longer.
08/19/2016 - BTIG Research began new coverage on Agios Pharmaceuticals, Inc. giving the company a "neutral" rating.
A number of brokerages recently issued reports on AGIO. The original version of this report can be viewed at https://www.themarketsdaily.com/2017/04/20/agios-pharmaceuticals-inc-agio-director-sells-112468-64-in-stock.html. Credit Suisse Group AG reissued an "outperform" rating and set a $61.00 price target on shares of Agios Pharmaceuticals in a research report on Tuesday. The stock of Agios Pharmaceuticals Inc (NASDAQ:AGIO) has "Buy" rating given on Monday, June 13 by Canaccord Genuity.
12/16/2016 - Agios Pharmaceuticals, Inc. had its "market perform" rating reiterated by analysts at Leerink Swann. One analyst has rated the stock with a sell rating, three have assigned a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company's stock. The most optimistic analyst sees the stock reaching $90.00 while the most conventional predicts the target price at $48.00. The current value of the RSI is 55.26 that is neither bought nor sold range.
The Company has 42.23 million shares outstanding and 35.94 million shares were floated in market. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Realized natural gas price, before the impact of derivatives and including transportation costs, averaged $2.68 per Mcf during the first quarter of 2017, a $0.63 per Mcf differential to the average trade month NYMEX settled price. Following the completion of the transaction, the chief executive officer now owns 3,000 shares in the company, valued at $175,860.